Induction of human immunodeficiency virus neutralizing antibodies using fusion complexes

• Published in: Microbes and infection Vol. 8; no. 6; pp. 1424 - 1433
• Main Authors: Zipeto, Donato, Matucci, Andrea, Ripamonti, Chiara, Scarlatti, Gabriella, Rossolillo, Paola, Turci, Marco, Sartoris, Silvia, Tridente, Giuseppe, Bertazzoni, Umberto
• Format: Journal Article
• Language: English
• Published: Lausanne Elsevier SAS 01.05.2006; Amsterdam Elsevier; Paris
• Subjects: Animals; Biological and medical sciences; CD4 Antigens - immunology; Cell Fusion - methods; CHO Cells; Cricetinae; Enzyme-Linked Immunosorbent Assay; Fundamental and applied biological sciences. Psychology; Fusion complex; HIV Antibodies - biosynthesis; HIV Antibodies - blood; HIV Antibodies - immunology; HIV Envelope Protein gp120 - immunology; HIV Envelope Protein gp41 - immunology; HIV Infections - immunology; HIV-1 - immunology; Human immunodeficiency virus 1; Immunization - methods; Membrane fusion; Mice; Mice, Inbred BALB C; Microbiology; Miscellaneous; Neutralization Tests; Neutralizing antibodies; NIH 3T3 Cells; Receptors, CCR5 - immunology; Recombinant Fusion Proteins - immunology; Virology; Membrane fusion; Neutralizing antibodies; Fusion complex; Virus; Retroviridae; Human immunodeficiency virus; Lentivirus; Neutralizing antibody
• ISSN: 1286-4579; 1769-714X
• DOI: 10.1016/j.micinf.2006.03.001

Human immunodeficiency virus-1 (HIV-1) infects cells by membrane fusion that is mediated by the envelope proteins gp120/gp41 and the cellular receptors CD4 and CCR5. During this process, some conserved viral epitopes are temporarily exposed and may induce a neutralizing antibody response when fixed in the fusogenic conformation. These transient structures are conserved and may be effective antigens for use in an anti-HIV-1 vaccine. In this study we tested different conditions of preparation of fusion complexes inducing neutralizing antibodies against both R5 and X4 tropic HIV-1 strains. Cell lines expressing HIV-1 gp120/gp41 and CD4–CCR5 were prepared and conditions for producing fusion complexes were tested. Complexes produced at different temperature and fixative combinations were used to immunize mice. Results indicated that (a) fusion complexes prepared at either 21 °C, 30 °C or 37 °C were immunogenic and induced neutralizing antibodies against both R5 and X4 HIV-1 heterologous isolates; (b) after extensive purification of antibodies there was no cytotoxic effect; (c) complexes prepared at 37 °C were more immunogenic and induced higher titers of neutralizing antibodies than complexes prepared at either 21 °C or 30 °C; (d) the fixative used did not affect the titer of neutralizing antibodies except for glutaraldehyde which was ineffective; (e) the neutralizing activity was retained after CD4–CCR5 antibody removal. The production of higher titers of neutralizing antibody with fusion complexes prepared at 37 °C, as compared to lower temperatures, may be related to the induction of antibodies against many different conformation intermediates that subsequently act synergistically at different steps in the fusion process.